Literature DB >> 2175791

Multiple mechanisms of xanthine actions on airway reactivity.

R E Howell1.   

Abstract

Xanthines are effective in the treatment of asthma, but the mechanism of action remains unclear. Pulmonary effects of seven xanthines, exhibiting a range of potencies as cyclic nucleotide phosphodiesterase (PDE) inhibitors and as adenosine antagonists, were investigated in anesthetized and ventilated guinea pigs. The bronchodilator effects of xanthines, determined from reversal of bronchoconstriction induced by aerosols of histamine and carbachol, correlated with their relative potencies as cyclic AMP-PDE inhibitors. The hypotensive effects of xanthines at bronchodilator doses were also consistent with PDE inhibition. Prophylactic effects of xanthines against bronchoconstriction induced by an aerosol of ovalbumin in sensitized guinea pigs, or by aerosols of leukotriene D4 and platelet-activating factor (PAF) in normal guinea pigs, occurred by a mechanism unrelated to bronchodilation and could not be readily attributed to PDE inhibition or adenosine A1/A2 receptor antagonism. There was a close association between inhibition of the responses to antigen and leukotriene D4, suggesting a common mechanism of action, but these effects gave a different profile from inhibition of the response to PAF. In addition, PAF-induced hypotension was unaffected in animals in which PAF-induced bronchoconstriction was inhibited, suggesting a mechanism other than PAF receptor antagonism. These results indicate that the bronchodilator, antiallergic and anti-inflammatory effects of xanthines occur through multiple molecular mechanisms of action, including at least one unknown mechanism. Furthermore, 8-phenyltheophylline produces these prophylactic effects at a dose that does not produce the cardiovascular or emetic side effects associated with xanthines, thereby exhibiting unique characteristics of potential therapeutic importance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175791

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers.

Authors:  M C Braat; R E Jonkers; E H Bel; C J Van Boxtel
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 2.  Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease.

Authors:  In-Ah Lee; Alan Kamba; Daren Low; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 3.  Theophylline. Current thoughts on the risks and benefits of its use in asthma.

Authors:  S S Nasser; P J Rees
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

4.  A cell-based PDE4 assay in 1536-well plate format for high-throughput screening.

Authors:  Steven A Titus; Xiao Li; Noel Southall; Jianming Lu; James Inglese; Michael Brasch; Christopher P Austin; Wei Zheng
Journal:  J Biomol Screen       Date:  2008-06-30

Review 5.  Differential pharmacokinetics of theophylline in elderly patients.

Authors:  Akihiro Ohnishi; Motokazu Kato; Jun Kojima; Hideki Ushiama; Maki Yoneko; Hiroyuki Kawai
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

6.  The Use of Antiallergic and Antiasthmatic Drugs in Viral Infections of the Upper Respiratory Tract.

Authors:  Nils Åberg
Journal:  Clin Immunother       Date:  2012-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.